Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension

Author: Perazella M.A.

Source: Expert Opinion on Drug Safety, Volume 2, Number 1, 1 January 2003 , pp. 37-47(11)

Publisher: Informa Healthcare

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Dialysis-associated hypotension is a morbid problem in haemodialysis patients. Employment of midodrine at the start of dialysis has reduced the severity and frequency of hypotensive episodes in these patients. Through selective alpha

₁-adrenergic receptor-binding, desglymidodrine, the active metabolite of midodrine, raises blood pressure by enhancing venous and arterial tone. This medication has been demonstrated to be effective and safe in the acute and chronic treatment of haemodialysis-associated hypotension in end stage renal disease patients.

Keywords: blood pressure; dialysis-associated hypotension (DAH); haemodialysis; midodrine

Document Type: Review article

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$99.00 plus tax Refund Policy